imaging, or when there is hydrocephalus on imaging but good results on clinical examination. 2, 16, 22 This is further confounded because IVH with or without hydrocephalus occurs with higher-volume ICH, 5, 25 and signs such as nausea/vomiting, headache, and drowsiness can be caused by ICH, IVH, and hydrocephalus.
To our knowledge, there are no published studies examining characteristics of IVH that may lead to symptomatic hydrocephalus requiring EVD in cases where patients are not immediately treated with ventriculostomy. Thus, we conducted a retrospective review of a cohort of patients with IVH to identify factors associated with the development of symptomatic hydrocephalus requiring EVD after IVH and its clinical timeframe.
methods
After Institutional Review Board approval, electronic clinical records from 2007 to 2014 were searched for the terms "intraventricular hemorrhage" or "IVH." The search was done using a hospital resource called the Data Discovery and Query Builder, which searches all forms of documentation, including hospital admission, daily progress, and hospital summary notes, and was designed jointly by the Mayo Clinic and IBM. Inclusion criteria were patients ≥ 18 years old with IVH after ICH, trauma, tumor, or vascular pathologies. Exclusion criteria were IVH with more than minimal subarachnoid hemorrhage (because EVD is used commonly in our practice for patients with only mild symptoms of hydrocephalus), layering IVH only, patients who had only 1 CT scan at presentation and were immediately treated with EVD, ventricular trapping, and catastrophic hemorrhages treated solely with palliative measures. The primary outcome was symptomatic hydrocephalus requiring EVD, including patients who were offered EVD but did not have the intervention due to conservative goals of care. Symptomatic hydrocephalus was defined as radiologically proven hydrocephalus causing more than drowsiness (i.e., patients would not open eyes to voice and/or follow commands). Placement of EVD at our institution generally conforms to current AHA guidelines, with a preference to follow clinical exams in patients with IVH and hydrocephalus who are able to follow commands. In patients who were comatose with IVH but without radiographic hydrocephalus, EVD was placed if successive CT scans showed ventricular enlargement.
Records of patients who met inclusion criteria were examined for age; comorbidities including history of hypertension, diabetes, hyperlipidemia, stroke, antiplatelet therapy and anticoagulation; etiology of hemorrhage; location of hemorrhage; ICH score; time of onset of hemorrhage (when onset was unwitnessed, this time was based on when the patient was last known to be normal); Glasgow Coma Scale (GCS) score; CT imaging characteristics such as hemorrhage size, midline shift, amount of IVH, ventricular rebleeding, and degree of hydrocephalus; EVD placement; shunt placement; mortality; and disability as categorized using the modified Rankin Scale (mRS). Poor outcome was defined as an mRS score ≥ 3. The modified Graeb Score (mGS) was used to measure the extent of IVH. 14 4, 21 The ABCD/2 method was used to evaluate hemorrhage volume. 9 Hydrocephalus was scored using the method of Stein et al. 22 as follows: 0, absent; 1, mild, widening of 1 temporal horn in the absence of brain atrophy; 2, moderate, dilation of 1 temporal horn and at least 1 frontal horn with sulcal effacement over at least 1 lobe; 3, severe, moderate hydrocephalus with sulcal effacement over 2 areas or bilateral compression of basilar cisterns. Scores used in the analysis were the most severe of serial-analyzed CT scans, and only CT scans obtained during hospitalization were used for analysis. The followup period for patients who survived hospitalization was 1-12 months. All patients were treated in either a trauma or neurological intensive care unit.
Statistical analysis using a chi-square test, Student's t-test, and the Mann-Whitney test was performed to determine characteristics that were statistically significantly different between groups. The receiver operating characteristic was used to determine binary cutoff values for continuous or ordinal variables. These variables were then considered for entry into univariate logistic regression analysis. Significant univariate variables were included in the multivariate model and excluded in a forward stepwise fashion by least-significant variable until all included variables had p < 0.05 or the model was maximally fitted.
results
Two hundred twenty patients were screened. Twentyone patients had EVD placed after only 1 CT scan and were excluded from the study. One hundred five patients met the study criteria. Of those, 44 patients (41.9%) had hydrocephalus on initial imaging and 30 (28.6%) developed symptomatic hydrocephalus that required EVD. Fourteen of these 30 patients (46.7%) were offered but declined EVD secondary to goals of care. Table 1 summarizes the characteristics of the entire population and comparisons between the EVD and No-EVD groups.
There were no differences between the EVD and No-EVD groups regarding medical comorbidities. The majority of patients (n = 90, 85.7%) had IVH secondary to spontaneous ICH, with deep hematomas (n = 61, 58.1%) predominating over lobar hematomas (n = 38, 36.2%). Ta (Table 3 ). The AUC (area under the receiver operating characteristic curve) for this model was 0.84.
In-hospital mortality for the entire population was 22.1% (n = 23), whereas for the EVD and No-EVD groups it was 53.5% (n = 16) and 9.5% (n = 7), respectively (p < 0.001). Poor outcome for the entire population was 54.3% (n = 57), whereas for the EVD and No-EVD groups it 
discussion
Studies on IVH and hydrocephalus have focused on incidence, radiographic assessment, treatment, and prognostication. 1, 3, 5, 6, 8, 10, 14, 17, 19, 22, 23, 25, 26 No previous study has directly investigated IVH and hydrocephalus regarding hemorrhage location and volume, although a few have made observations while examining other primary outcomes.
Young et al. 26 studied the prognostic significance of IVH in supratentorial hemorrhage using volumetric analysis of CT scans in 47 patients. They found that hydrocephalus, the number of ventricles containing blood, the volume of blood in the ventricles, and blood in the fourth ventricle were associated with worse outcome. There was no direct analysis of the relationship between ventricular blood and symptomatic hydrocephalus, but patients with higher IVH volumes had higher mean hydrocephalus and ventricular involvement scores, leading to the remark that "there was a high correlation between ventricular blood volume, the number of ventricles involved, 4th ventricular involvement, and extent of hydrocephalus." 26 Diringer et al. 3 examined the effect of hydrocephalus in the outcomes of 81 patients with spontaneous supratentorial ICH, 40 of whom developed hydrocephalus. Hydrocephalus was an independent predictor of mortality on multivariate analysis [OR 1.63, CI 1.20-2.31 (p = 0.001)], overcoming hematoma size and IVH. Patients who developed hydrocephalus had a higher mean IVH score than those who did not [5.0 ± 3.5 (range 0-11) vs 0.8 ± 1.6 (range 0-6), p < 0.005], although patients who developed hydrocephalus without IVH were also included in the cohort. Patients who received a ventriculostomy (n = 13) had a higher mean IVH score than those who did not (7.4 ± 3.6 vs 3.9 ± 2.6, p < 0.004). However, the number of patients with IVH was not specified.
Nishikawa et al. 19 examined 100 patients with ICH, 35 of whom had IVH, to determine the effect of IVH on hydrocephalus and clinical exam. Eight patients in the IVH group developed hydrocephalus. The unmodified GS was used to score IVH, and a GS ≥ 6 was associated with increased risk of acute hydrocephalus [OR 23.99, CI 3.24-177.38 (p = 0.002)].
Hwang et al. 8 studied IVH in 73 patients to determine the predictive value of the Graeb, IVH, and LeRoux scores on outcomes. Volumes of IVH were also assessed. Thirtynine patients (53.4%) were treated with EVD, of whom 32 (82.1%) had hydrocephalus. Of the 34 patients (46.6%) not treated with EVD, 17 (50.0%) had hydrocephalus. The mean IVH volume for patients with EVD was 23.44 ± 26.24 ml versus 9.21 ± 11.30 ml in patients without EVD (p = 0.003).
In a more recent study, Herrick et al. 7 examined deter- minants of EVD placement in 183 patients with spontaneous ICH, finding that GCS score ≤ 8, a total unmodified GS > 5, and nonlobar ICH ≤ 30 ml were independent predictors on multivariate analysis. Sixty-seven patients required EVD, and had a higher IVH volume than those who did not (31.8 ± 3.3 ml vs 12.7 ± 2.0 ml, p = 0.03). Regarding timeframe, patients who had an EVD placed after 5 days (n = 4) were included in the No-EVD group. The patients in the EVD group had drains placed at 2.8 days or sooner. In contrast to the above studies, we excluded patients who presented immediately with clearly symptomatic hydrocephalus and who were treated immediately with EVD (in whom the decision is straightforward) to better determine factors leading to delayed need for EVD placement (which are the cases where the best therapeutic approach is initially uncertain). In addition, ours is the only study to examine IVH patterns and their roles in hydrocephalus and to use the modified instead of the original GS. In our study, the development of hydrocephalus requiring EVD was significantly associated with IVH location and volume. No patients with IVH confined only to the lateral ventricle and only 2 patients with IVH in the third and fourth or fourth ventricle alone required EVD. The patients at highest risk for EVD requirement were those with IVH in ≥ 3 ventricles. Still, almost half of patients with panventricular IVH did not require EVD (Figs. 1 and 2) . Patients who required EVD had a higher median mGS, signifying that IVH volume is a key factor for EVD requirement once IVH is present in ≥ 1 central ventricle. Yet, the volume of IVH (as gauged by mGS) varied substantially among patients requiring EVD (range of mGS 5-29).
The time to development of symptomatic hydrocephalus also varied. However, we identified 2 groups separated not by hours but by days. This suggests that symptomatic hydrocephalus after IVH is a dynamic process that is difficult to predict in individual cases, both in terms of the risk of its occurrence and the timing of its development. There is probably an interplay of coagulative, molecular, and anatomical factors 24 affecting the dilutive capacity of CSF that may explain this variation. The simulation of IVH in animal models supports this argument because the simple injection of blood into the ventricles is not sufficient to produce clot. Alteration of the blood, such as injecting clotted blood or blood with thrombin, is often required to obtain ventricular casting leading to dilation and obstruction of CSF flow. 11, 12, 20 This variability is probably why practices and indications for EVD vary widely. 2 The current guidelines from the AHA and the American Stroke Association do not endorse EVD unless there is a decreased level of consciousness. 15 However, there are more aggressive practices based on the location and amount of blood alone. Naff 16 stated, "IVH that is not causing hydrocephalus but is apparently occluding one or both foramina of Monro or the third ventricle should be treated with EVD because obstructive hydrocephalus may develop precipitously." A study on IVH by Stein et al. 22 used this recommendation and stated in their Methods section that "if blood completely clogged the third ventricle or bilateral occlusion of the foramina of Monro was present on the CT scan, patients received bilateral EVDs." Yet, after critical analysis, they conceded that EVD placement might have been unnecessary in 10.6% of their patients. 22 Although IVH per se may be detrimental for neurological recovery, there is no definite proof that EVD has a beneficial effect in patients without symptomatic hydrocephalus. 18 Our results indicate that it is reasonable to observe patients with IVH (even those with panventricular involvement) as long as they do not have symptomatic hydrocephalus. Yet, these patients must be monitored closely, especially if they have very extensive IVH, coma without hydrocephalus, or dilation of the fourth ventricle. Furthermore, ongoing investigations, such as the Clinical Trial on Treatment of Intraventricular Hemorrhage (CLEAR IVH), 13 might provide evidence supporting a more aggressive approach in the future.
This study has the limitations inherent to a retrospec- tive design. The primary end point was EVD requirement because of the development of symptomatic hydrocephalus. We acknowledge that this is a clinical diagnosis that may be sometimes difficult to make in patients with a large ICH, in whom deterioration may be explained by more than one mechanism. We also acknowledge that the retrospective design means there was no formal standardization of EVD placement. However, as stated in the Methods section, our practice conforms to AHA guidelines. Our exclusion of patients who had an EVD without successive CT scans allowed us to ensure that patients receiving EVD had both evidence of radiographic progression of ventricular caliber and a clinical exam consistent with hydrocephalus.
The study also included a mixed etiology of IVH, which may have confounded the study results. However, whatever the etiology, the development of hydrocephalus after IVH is the same, and we included various etiologies to be more applicable to the variety of IVH seen in clinical practice. Also, although the mGS has been shown to correlate with IVH volume, 12 it is not a direct volumetric measurement and may not have enough resolution to detect slight differences. However, more precise volumetric analysis is not practical in a clinical setting, and the goal of this study was to determine factors that can be used at the bedside to identify patients at risk for EVD requirement. The functional outcomes in the EVD group may have been negatively affected because some patients who were not treated with EVD, despite developing EVD requirement, were included in the study group. This was intentional because functional outcomes were not a primary study end point.
conclusions
In our population, the majority of patients with IVH but no symptomatic hydrocephalus upon admission did not subsequently require EVD. Whereas no patients with unilateral ventricular hemorrhage required EVD, half of the patients with panventricular hemorrhage required it, and those who required EVD had a higher ventricular volume of blood. Patients with coma, mGS > 13, and dilation of the fourth ventricle were more likely to require EVD. Most of these patients (83.3%) did so within 24 hours. However, there were patients with extensive IVH and a good clinical exam who did not require EVD, and there was a minority of patients who developed EVD requirement after 48 hours.
Based on our results, hydrocephalus after IVH is variable and difficult to predict. No definite pattern or amount of IVH indicates which patients will develop hydrocephalus and will need EVD placement, although some guiding principles could be ascertained. We believe that patients with IVH in more than one ventricle should be monitored for at least the first 24 hours in the intensive care unit for the possibility of developing symptomatic hydrocephalus requiring EVD. Patients with extensive IVH and no hydrocephalus, especially if the clinical exam is poor, should undergo repeat scanning at a short time interval, as the majority of hydrocephalus developed over hours. Clinical and radiological monitoring should be stricter and more prolonged in patients who are poorly responsive and in those with panventricular IVH, larger IVH volumes, and extensive clotting in the fourth ventricle. 
